Tirzepatide Safe and Tolerable in Treatment of Type 2 Diabetes, Researchers Find

By Derek Bagley

June 5, 2023

Tirzepatide – the dual glucose-dependent insulinotropic peptide (GIP) and glucagon-like peptide-1 receptor agonist (GLP-1 RA) injection used to treat type 2 diabetes – is safe and has a tolerable adverse event (AE) profile in its role in the management of T2D, and possibly obesity, according to a study recently published in the Journal of the […]

To view the full Member Resource, please Log in

TOPICS IN THIS ARTICLE:

Obesity Trends and Insights

Join the Global Movement Advancing Endocrine Science and Medicine

Become a part of a community of 18,000-plus endocrine investigators and clinicians who conduct research and provide quality patient care in more than 100 countries. Advance your career and the field of endocrinology through our many educational, leadership and advocacy opportunities.

Join Today

RELATED ARTICLES

Could Moving Obesity Diagnosis Beyond BMI Delay Treatment?

When the Scale Isn’t the Whole Story: Three Principles for Practicing Person-Centered Obesity Care

Heavy Wears the Crown: Obesity’s Link to Dementia

Health Topics

Patient Populations